Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as OTX-TIC low dose Travoprost Intracameral Implant
OTX-TIC low dose Travoprost Intracameral · 1 trial · 2 indications
IOP changes from baseline 8 AM, 10 AM, and 4 PM at Week 2, Week 6, and Week 12 in the study eye.
| Arm | Type | Description |
|---|---|---|
| OTX-TIC Low Dose | EXPERIMENTAL | Travoprost Intracameral Implant low dose |
| OTX-TIC High Dose | EXPERIMENTAL | Travoprost Intracameral Implant high dose |
| Durysta | ACTIVE_COMPARATOR | Bimatoprost Intracameral Implant 10 µg |
| Name | Type | Description |
|---|---|---|
| OTX-TIC low dose Travoprost Intracameral Implant | DRUG | OTX-TIC implant is injected into the anterior chamber of the eye. |
| OTX-TIC high dose Travoprost Intracameral Implant | DRUG | OTX-TIC implant is injected into the anterior chamber of the eye. |
| Durysta, Bimatoprost Intracameral Implant 10 µg | DRUG | Durysta is injected into the anterior chamber of the eye. |
Inclusion Criteria: * Are 18 years of age or older at the time of screening * Provide written informed consent and are able to comply with all study requirements * Are willing to withhold glaucoma medications according to the study requirements, and in the opinion of the investigator can do so with...
Top 3 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular, high elution |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | bimatoprost |
OTX-TIC low dose Travoprost Intracameral is being developed for the treatment of open angle glaucoma and ocular hypertension. It is an intracameral implant designed to deliver travoprost directly into the eye. It is investigational and has not been approved by the FDA.
OTX-TIC low dose Travoprost Intracameral is being developed by Ocular Therapeutix, Inc., which trades on the Nasdaq under the ticker symbol OCUL. The company is focused on ophthalmic therapies.
OTX-TIC low dose Travoprost Intracameral is in Phase 2 clinical development. The Phase 2 trial has been completed. It remains an investigational therapy and is not approved for commercial use.
OTX-TIC low dose Travoprost Intracameral has been studied in a completed Phase 2 trial, NCT05335122, titled "A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)." The trial enrolled 83 patients in the United States.
Yes, OTX-TIC low dose Travoprost Intracameral and OTX-TIC low dose Travoprost Intracameral Implant refer to the same investigational therapy. The longer name includes the implant designation, but both describe the same travoprost-containing intracameral implant developed by Ocular Therapeutix.